Skip to content

Palbolib

Generic Name
Palbociclib
Therapeutic Area
Oncology
Therapeutic Class
Antineoplastic – CDK4/6 Inhibitor
Dosage Form
Tablets
Strength
100 mg & 125 mg
Pack Size
20’s & 21’s
Registration Number
129031 & 129030

Overview

Palbociclib is an oral cyclin-dependent kinase (CDK) 4/6 inhibitor that regulates cell-cycle progression by blocking the CDK4/6 pathway. It helps prevent cancer cells from progressing through the cell cycle and is used in combination with endocrine therapy for eligible patients with HR-positive, HER2-negative advanced or metastatic breast cancer.

Indication

Used in the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.